Tempus AI shares pulled back Friday after a five-day rally of nearly 40% driven by CEO Eric Lefkofsky's reimbursement projections at the ...

Vera Therapeutics, Inc. ( VERA) reported that in the pivotal ORIGIN 3 trial of TRUTAKNA (atacicept-vymj), an FDA-approved dual BAFF and APRIL inhibitor, it stabilised kidney function and prevented ...

GSK slides 1.82% today to GBX1865.50 despite ongoing progress in oncology and vaccines, with volatility remaining elevated.

Deals: Apollo Global Management is in negotiations to acquire Johnson & Johnson’s DePuy Synthes orthopedics business in a ...

Tempus AI (TEM) stock jumped 15% Thursday after CEO projected up to $400M in Medicare revenue. The stock has rallied 92% since its July low of $41.55.

Tempus AI (TEM) stock jumped 15% Thursday after CEO outlined Medicare revenue expectations up to $400M. Shares have surged 92% since July bottom.

Tempus AI (TEM) stock surged 15% Thursday as CEO outlined up to $400M in Medicare revenue. TEM is up 92% from its July low.

Most drug licensing deals with China will be safe from rules being drafted by the U.S. Treasury Department, Reuters reports.

Companies are responding to patent cliffs and the increased cost of research and development for more complex products.

GSK (LSE: GSK) has delivered a 58.4% share price return over the past five years, putting real pressure on the question of whether current earnings justify ...

According to Sharecast on September 18, 2026, Berenberg upgraded GSK from Hold to Buy and lifted its target price on the stock from GBP 20 to GBP 22, arguing that recent business-development ...

On 8, 2026, CNBC reported that AstraZeneca PLC (NYSE:AZN) released full results from two successful late-stage trials of tozorakimab, an experimental drug for chronic obstructive pulmonary ...